BSPED recommendations for the use of once-weekly long-acting growth hormone therapy in children with growth hormone deficiency

Recommendations for the use of once-weekly long-acting growth hormone therapy in children with growth hormone deficiency - British Society for Paediatric Endocrinology and Diabetes (BSPED)

Long-acting growth hormone (LAGH) is now available in the UK and is recommended by NICE (2023) as an option for the treatment of growth hormone deficiency for children and young people aged three years and over.

Currently only one LAGH preparation is licenced (somatrogon) but other preparations are likely to become available. This guidance therefore focuses on somatrogon and will be updated when new LAGH preparations are accessible to patients in the UK.


Read full Guideline